<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Exercise-induced bronchoconstriction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Exercise-induced bronchoconstriction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Exercise-induced bronchoconstriction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M O'Byrne, MB, FRCP(C), FRSC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Exercise-induced bronchoconstriction describes the acute onset of bronchoconstriction occurring during or, more frequently, minutes after exercise. The term "exercise-induced asthma" is often used to describe episodic bronchoconstriction following exercise, but this wording is potentially misleading, since exercise is not an independent risk factor for asthma, but rather a trigger of bronchoconstriction in patients with underlying asthma [<a href="#rid1">1</a>]. In fact, there is some speculation that decreased physical activity is a risk factor for asthma, and that exercise may be helpful in preventing the onset of asthma in children [<a href="#rid2">2</a>]. Thus, the term exercise-induced bronchoconstriction (EIB) is a more accurate reflection of the underlying pathophysiology and is generally preferred.</p><p>The clinical manifestations, diagnosis, and management of exercise-induced bronchoconstriction will be discussed here. The clinical manifestations, evaluation, and management of asthma are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5742.html" rel="external">"Asthma in children younger than 12 years: Initial evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/569.html" rel="external">"Pulmonary function testing in asthma"</a> and  <a class="medical medical_review" href="/z/d/html/13585.html" rel="external">"Wheezing phenotypes and prediction of asthma in young children"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">"Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The estimated prevalence of exercise-induced bronchoconstriction (EIB) varies from approximately 5 to 20 percent in the general population [<a href="#rid3">3-6</a>]. In comparison, up to 90 percent of patients with symptomatic asthma have some degree of EIB [<a href="#rid7">7</a>]. The magnitude of EIB is most strongly correlated with the underlying degree of airway hyperresponsiveness and the presence of airway inflammation, as measured by the number of airway eosinophils [<a href="#rid8">8,9</a>]. Thus, many patients with mild, episodic asthma characterized by minimally increased airway responsiveness and mild airway inflammation do not experience clinically significant bronchoconstriction even with strenuous exercise.</p><p>The prevalence of EIB appears to be higher among elite athletes and has been evaluated in a number of studies [<a href="#rid6">6,10-13</a>]. As an example, in a study of athletes participating in the summer Beijing and Athens Olympic Games, the sports most commonly associated with a Therapeutic Use Exemption for asthma were swimming, cycling, triathlon, pentathlon, and rowing, with prevalences of approximately 18, 16, 12, 13, 7 percent, respectively [<a href="#rid10">10</a>]. In contrast, the prevalence of asthma among athletes in disciplines without endurance demands, such as gymnastics, fencing, and sailing, was less than 5 percent. In a separate study, positive eucapnic hyperventilation was noted in 39 percent of swimmers and 24 percent of winter sport athletes [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Minute ventilation, the volume of air inhaled or exhaled from a person's lungs per minute, rises with exercise. EIB probably results from changes in airway physiology triggered by the large volume of relatively cool, dry air inhaled during vigorous activity [<a href="#rid14">14,15</a>]. This is supported by the finding that EIB is attenuated when the inspired gas is more fully humidified and closer to body temperature [<a href="#rid16">16,17</a>]. The effect of large-volume dry air inhalation on airway surface osmolality may be the primary stimulus responsible for bronchoconstriction [<a href="#rid18">18</a>]. Other relevant observations regarding EIB include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Levels of bronchoconstrictive and inflammatory mediators are increased, particularly leukotrienes LTC4 and LTD4 [<a href="#rid19">19</a>], histamine [<a href="#rid20">20</a>], and interleukin (IL)-8 [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral Th2-type lymphocytes are activated, with an increase in T cells expressing CD25 (IL-2R), and B cells expressing CD23 [<a href="#rid22">22</a>]. These changes favor production of IgE and activation of eosinophils. (See  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development", section on 'Th2 cells'</a> and  <a class="medical medical_review" href="/z/d/html/5542.html" rel="external">"The biology of IgE", section on 'Regulation of synthesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eosinophil influx and activation, measured using eosinophilic cationic protein levels, sputum eosinophils, or peripheral eosinophil counts, have been noted in some [<a href="#rid23">23,24</a>], but not all [<a href="#rid17">17,25</a>], studies of experimental EIB.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, the fraction of exhaled nitric oxide (FE<sub>NO</sub>) levels, which generally reflect airway inflammation, do not appear to correlate well with the development or severity of EIB [<a href="#rid26">26-28</a>]. (See  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with exercise-induced bronchoconstriction (EIB) typically have initial bronchodilation during the first six to eight minutes of exercise [<a href="#rid29">29,30</a>]. The initial bronchodilation is followed by <strong>bronchoconstriction</strong>, which begins by three minutes after exercise, generally peaks within 10 to 15 minutes, and resolves by 60 minutes  (<a class="graphic graphic_figure graphicRef64910" href="/z/d/graphic/64910.html" rel="external">figure 1</a>). Typical symptoms are shortness of breath, chest tightness, and cough. Associated hoarseness or stridor is uncommon and should raise the possibility of paradoxical vocal fold motion. (See  <a class="medical medical_review" href="/z/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a>.)</p><p>In most patients with EIB, bronchoconstriction is followed by a refractory period, during which repeated exertion causes less bronchoconstriction [<a href="#rid31">31</a>]. This refractory period is generally less than four hours. Inhibitory prostaglandins (particularly prostaglandin E2) released during the refractory period probably protect against repeated episodes of EIB  (<a class="graphic graphic_figure graphicRef78975" href="/z/d/graphic/78975.html" rel="external">figure 2</a>) [<a href="#rid32">32</a>].</p><p>Acute bronchoconstriction was previously believed to be followed by late phase bronchoconstriction in some patients [<a href="#rid33">33</a>]. Findings in subsequent studies have been variable [<a href="#rid34">34,35</a>]; however, it does appear that the risk and severity of late phase bronchoconstriction due to EIB is substantially less than that associated with allergen-induced asthma [<a href="#rid36">36,37</a>].</p><p>Among atopic asthma patients with sensitization to inhalant allergens, EIB may be more likely to occur when the exercise includes exposure to the relevant allergen. As an example, runners are more likely to report exercise-related asthma symptoms during their pollen or mold allergy season [<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of exercise-induced bronchoconstriction (EIB) is based on the combination of compatible clinical symptoms (eg, exercise-related symptoms of dyspnea, cough, or wheeze) and demonstration of reversible airflow limitation in response to exercise or a surrogate challenge [<a href="#rid6">6,30,40</a>]. In patients with well-documented asthma and typical asthma symptoms following exercise, formal exercise testing may not be needed unless symptoms do not resolve with, or are not prevented by, pretreatment with inhaled beta agonists. </p><p>In patients without documented asthma, further assessment is helpful to ensure that alternative causes of dyspnea are not overlooked and that unnecessary therapy is not prescribed. This is particularly true when an adult develops new onset exercise related symptoms. Formal testing is also helpful in evaluating highly trained athletes, as exercise related respiratory symptoms are poor predictors of EIB in this setting [<a href="#rid6">6,41-43</a>]. (See  <a class="medical medical_review" href="/z/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise challenge</strong> – An exercise challenge test is the most direct and preferred way to establish a diagnosis of EIB [<a href="#rid30">30</a>]. This usually involves 6 to 10 minutes of ergometer or treadmill exercise, sufficient to raise the heart rate to 80 to 90 percent of the predicted maximum. A test is generally considered positive if the forced expiratory volume in one second (FEV<sub>1</sub>) decreases by 10 percent or more, although a fall of 15 percent is more diagnostic [<a href="#rid6">6,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/525.html" rel="external">"Bronchoprovocation testing", section on 'Exercise challenge'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surrogate provocation tests</strong> – Alternatively, surrogate tests to assess bronchial hyperresponsiveness (eg, eucapnic voluntary hyperventilation, <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a>, histamine, or <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> inhalation challenge) may be performed in specialized laboratories [<a href="#rid44">44,45</a>]. Depending on the available facilities, a surrogate test can be used instead of an exercise challenge test. Or, if the direct test is negative, an indirect test may identify patients with EIB who have a false negative exercise test [<a href="#rid46">46</a>]. Among the surrogate tests, eucapnic voluntary hyperventilation appears to have the greatest sensitivity for EIB [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/z/d/html/525.html" rel="external">"Bronchoprovocation testing", section on 'Eucapnic voluntary hyperpnea'</a> and  <a class="medical medical_review" href="/z/d/html/525.html" rel="external">"Bronchoprovocation testing", section on 'Pharmacologic challenge'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis in elite athletes</strong> – The International Olympic Committee and the World Anti-Doping Agency require an objective test to confirm the diagnosis of asthma, such as spirometry demonstrating airflow limitation with reversibility following inhaled bronchodilator OR a positive bronchoprovocation test, as described above [<a href="#rid40">40,46</a>]. (See <a class="local">'World Anti-Doping Agency'</a> below.) </p><p></p><p>Measurement of peak expiratory flow rates before and after exercise frequently leads to inaccurate results, but portable devices that record forced expiratory volume in one second (FEV<sub>1</sub>) are more accurate [<a href="#rid30">30</a>]. After a baseline value has been established, FEV<sub>1</sub> can be measured before and 2.5, 5, 10, 15, and 30 minutes after exercise and correlated with symptoms.</p><p class="headingAnchor" id="H6"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Other causes of exercise-induced dyspnea must be considered in the differential diagnosis of exercise-induced bronchoconstriction (EIB), particularly in patients who have no other manifestations of asthma, have normal baseline spirometry, and derive no benefit from pretreatment with bronchodilators. Central airway obstruction, paradoxical vocal fold motion (PVFM), laryngomalacia, exercise-induced anaphylaxis, interstitial lung disease, gastroesophageal reflux, poor cardiovascular conditioning, coronary heart disease, and exercise-induced dysrhythmias should be considered in adults who present with atypical exercise-induced dyspnea. A general approach to the diagnosis of dyspnea and wheezing illnesses are provided separately. (See  <a class="medical medical_review" href="/z/d/html/563.html" rel="external">"Evaluation of wheezing illnesses other than asthma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)", section on 'Evaluation'</a>.)</p><p>The following exercise-associated airway processes may be missed on routine pulmonary function testing. Diagnosis may require direct visualization or a high index of suspicion:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central airway obstruction</strong> – Features that suggest central airway obstruction include a lack of response to inhaled bronchodilator, associated hemoptysis, and risk factors for lung cancer or metastasis to the airway. (See  <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise-induced laryngeal obstruction (EILO)</strong> – The hallmark of EILO (previously known as paradoxical vocal fold motion and vocal cord dysfunction) is inspiratory stridor accompanied by respiratory distress that occurs during exercise. However, a portion of patients have expiratory stridor due to expiratory adduction of the vocal folds. (See  <a class="medical medical_review" href="/z/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a> and  <a class="medical medical_review" href="/z/d/html/119345.html" rel="external">"Exercise-induced laryngeal obstruction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise-induced laryngomalacia</strong> – Exercise-induced laryngomalacia is associated with inspiratory stridor during exercise caused by abnormal movement of the aryepiglottic folds into the endolarynx, resulting in subtotal glottic obstruction [<a href="#rid49">49-52</a>]. It is distinct from tracheomalacia. The diagnosis is made by flexible laryngoscopy during exercise. Exercise-induced laryngomalacia is a form of exercise-induced laryngeal obstruction. (See  <a class="medical medical_review" href="/z/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise-induced anaphylaxis</strong> – Exercise-induced anaphylaxis is characterized by the abrupt onset of signs and symptoms of anaphylaxis during exercise. Prodromal symptoms may include generalized pruritus, warmth, urticaria, and fatigue. A food co-factor may be implicated. Some patients develop laryngeal angioedema as a component, although hypotension and/or cardiovascular collapse are more common. (See  <a class="medical medical_review" href="/z/d/html/384.html" rel="external">"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise-associated reflux</strong> – Laryngopharyngeal reflux during exercise can mimic mild symptoms of EIB and exercise-induced anaphylaxis, including flushing, throat discomfort, dysphonia, and chest tightness/cough. However, it is not associated with severe dyspnea, pruritus, or urticaria. (See  <a class="medical medical_review" href="/z/d/html/6852.html" rel="external">"Laryngopharyngeal reflux in adults: Evaluation, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysfunctional breathing</strong> – Dysfunctional breathing (eg, hyperventilation, deep sighing, thoracic-dominant breathing, mouth breathing, accessory muscle use at rest, and thoraco-abdominal asynchrony) can contribute to persistent dyspnea during exercise and may be present in association with exercise-induced bronchoconstriction or as an independent diagnosis [<a href="#rid53">53-57</a>]. Physical therapy may help by improving muscle balance, posture, and diaphragmatic function [<a href="#rid57">57</a>].</p><p></p><p>The differential diagnosis of EIB is similar among children. In one retrospective review, treadmill exercise testing was performed in 142 children referred to a pediatric allergy and pulmonology clinic with exercise-induced dyspnea who had no other signs of asthma or in whom treatment with beta-2-agonists had failed [<a href="#rid58">58</a>]. Symptoms of exercise-induced dyspnea were reproduced in 82 percent. Among these 117 children, only 11 (9 percent) had EIB (defined by reproduction of symptoms and ≥15 percent decrease in FEV<sub>1</sub> from baseline). Other diagnoses included normal physiologic exercise limitation (63 percent), restrictive abnormalities (13 percent), vocal cord dysfunction (11 percent); laryngomalacia (2 percent), and hyperventilation and supraventricular tachycardia, each in one patient.</p><p class="headingAnchor" id="H7"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The combination of general measures and pharmacologic intervention can prevent exercise-induced bronchoconstriction (EIB) in almost all patients. A major goal is to <strong>ensure that exercise is not avoided</strong> by patients with EIB. Asthmatics should exercise as much as desired and should be encouraged by the fact that athletes have won Olympic medals and played professional sports despite symptomatic asthma.</p><p class="headingAnchor" id="H4091103272"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Response to therapy can be assessed subjectively in terms of symptom control and exercise tolerance. Peak expiratory flow (PEF) measurement before and after exercise may be helpful, although measurements of forced expiratory volume in one second (FEV<sub>1</sub>) are more reliable [<a href="#rid30">30</a>]. If objective measurement of a patient's response to therapy is required, a formal exercise test, rather than the more widely available <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> challenge, should be considered [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/z/d/html/525.html" rel="external">"Bronchoprovocation testing"</a>.)</p><p>While monitoring of PEF at home or during athletic practice lacks documented benefits in prevention of EIB, sports medicine clinicians and athletic programs have utilized PEF monitoring to help detect athletes with subclinical or unrecognized bronchoconstriction. These athletes may be given a slower warm up, modified workout, and suggestions for improved compliance or better technique in inhaler use. Should the athlete continue to experience a reduction in PEF or frequent EIB, a medical evaluation for medication adjustment would likely be indicated. (See  <a class="medical medical_review" href="/z/d/html/568.html" rel="external">"Peak expiratory flow monitoring in asthma"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Nonpharmacologic measures to reduce EIB</span><span class="headingEndMark"> — </span>Improved understanding of the pathophysiology of EIB has resulted in general recommendations that can help reduce its severity. These measures are based upon observed relationships between the severity of bronchoconstriction and the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>The magnitude of minute ventilation</p><p class="bulletIndent1"><span class="glyph">●</span>The temperature and humidity of the inspired air</p><p></p><p>Improving a patient's cardiovascular fitness reduces the minute ventilation required for a given level of exercise, thereby decreasing the stimulus for bronchoconstriction. Similarly, bronchoconstriction is lessened when the inspired gas is warmer and more humid. Patients should be instructed to breathe through a loosely fitting scarf or mask when exercising in cold, dry conditions [<a href="#rid61">61,62</a>].</p><p>The role of a pre-exercise warm-up is unclear. Some studies suggest that high intensity and variable intensity warm-up routines attenuate the fall in forced expiratory volume in one second (FEV<sub>1</sub>), but data are conflicting [<a href="#rid46">46,63,64</a>]. Finally, ensuring that patients know when and how to use a metered dose or dry powder inhaler correctly can greatly enhance the efficacy of pharmacologic measures.</p><p>The role of controlling adverse environments in reducing symptoms of EIB has not been formally studied, although it seems reasonable to reduce chloramines in indoor pool environments, use a heat-exchanger or other face mask during cold weather endurance exercise, and, for urban athletes, schedule outdoor training around low-traffic hours [<a href="#rid30">30,65</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Selection of pharmacologic therapy</span><span class="headingEndMark"> — </span>Treatment of EIB has been studied primarily in patients with both EIB <strong>and</strong> underlying asthma [<a href="#rid30">30</a>]. Therapeutic options for patients with EIB as the <strong>only</strong> manifestation of airway hyperresponsiveness are less well researched. In general, if EIB occurs frequently in patients with poorly controlled asthma, the most important strategy is to improve overall asthma control [<a href="#rid30">30,66</a>]. Inhaled glucocorticoids and leukotriene-modifying agents are often useful in this regard. Prophylactic treatment of EIB prior to exercise, using an inhaled short-acting beta-2 agonist, should be considered in all patients with EIB, even if EIB is the sole manifestation of airway hyperresponsiveness. The following sections describe the pharmacologic management of various patient presentations  (<a class="graphic graphic_table graphicRef105874" href="/z/d/graphic/105874.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H11"><span class="h3">Pre-exercise treatments for EIB</span></p><p class="headingAnchor" id="H2280514039"><span class="h4">General approach</span><span class="headingEndMark"> — </span>Short-acting beta-agonists (SABAs; <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> [salbutamol], <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>) are the most effective therapy for quick relief of EIB. All patients who report exercise-related symptoms should have access to a SABA for quick relief and be instructed on correct technique. Two inhalations (eg, albuterol 90 mcg/inhalation) are generally sufficient; occasionally four inhalations are needed.</p><p><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> is generally <strong>not</strong> used for quick relief as bronchodilation is delayed (onset at 15 minutes and peak at one to two hours) compared with SABAs.</p><p>Patients who have well-controlled asthma, but frequently have asthma symptoms with exercise, should be instructed to use prophylactic treatment approximately 5 to 20 minutes before exercise, usually with two inhalations of a SABA (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>) [<a href="#rid30">30,67</a>]. An alternative is to use a combination <a class="drug drug_general" data-topicid="8524" href="/z/d/drug information/8524.html" rel="external">budesonide-formoterol</a> (160 mcg/4.5 mcg) inhaler, 1 inhalation 5 to 20 minutes prior to exercise [<a href="#rid66">66,68</a>]. (See  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults"</a>.)</p><p>Equipotent doses of <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>, and <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a> appear to be equally effective in providing short-term control of EIB, although the onset of action is slower with salmeterol than with the other agents  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 2</a>) [<a href="#rid69">69</a>]. However, frequent use of inhaled beta-agonists may lead to tolerance and decreased efficacy, and long-acting beta-agonists (eg, salmeterol, formoterol) should never be used as monotherapy in asthma [<a href="#rid70">70</a>]. Thus, it is preferable for athletes who exercise regularly to aim for sufficient control of their asthma that beta-agonist pretreatment is not routinely needed [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use"</a>.)</p><p>Children often present a difficult clinical situation by exercising vigorously and intermittently throughout the day making pretreatment prior to exercise difficult. In this setting, it might be tempting to add a long-acting inhaled beta-2 agonist (LABA; such as <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> and <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>) to provide protection against EIB for 12 or more hours [<a href="#rid71">71,72</a>]. However, LABAs are not recommended for monotherapy in asthma and should be prescribed in combination with inhaled glucocorticoid. Alternative strategies, such as use of leukotriene receptor antagonists, are described below. (See <a class="local">'Prolonged or recurrent exercise'</a> below.)</p><p class="headingAnchor" id="H1152256594"><span class="h4">Approach in patients with intolerance of short-acting beta-agonists</span><span class="headingEndMark"> — </span>Some patients are intolerant of the adverse effects of SABAs, such as jitteriness and increased heart rate. Several strategies can be used in these patients, including adjusting type or dose of SABAs or trials of alternative agents for EIB control.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altering SABA type, dose, or technique</strong> – For some patients, switching to an alternate SABA such as <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>, using a chamber device (spacer) to reduce oral deposition, or using one inhalation instead of two allows improved tolerance of SABA pretreatment. Levalbuterol is an isomer of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, R-albuterol. The use of levalbuterol and chamber devices are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults", section on 'Spacers and holding chambers'</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children", section on 'Spacers and holding chambers'</a> and  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Levalbuterol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukotriene receptor antagonists</strong> – LTRAs reduce EIB in most patients and improve recovery to baseline  (<a class="graphic graphic_table graphicRef77367" href="/z/d/graphic/77367.html" rel="external">table 3</a>) based upon a review of 11 randomized trials in the American Thoracic Society guideline [<a href="#rid30">30</a>]. Protection from EIB is apparent by two hours after a single dose of <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, and postexercise recovery is accelerated [<a href="#rid73">73,74</a>]. The long half-life of montelukast allows once-daily dosing with durable protection from EIB for up to 12 hours [<a href="#rid75">75,76</a>]. However, LTRAs are not effective in all patients [<a href="#rid77">77</a>]. While LTRAs can be used to prevent EIB, patients will need to keep a SABA on hand for quick relief of any breakthrough symptoms. (See  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> – When used to prevent EIB, the inhaled muscarinic antagonist (anticholinergic agent), ipratropium, reduces the decrease in FEV<sub>1</sub> relative to placebo, but is less effective than SABAs [<a href="#rid30">30,78,79</a>]. For patients who are intolerant of SABAs, pretreatment with ipratropium will likely provide partial protection against EIB.</p><p></p><p class="headingAnchor" id="H1439411521"><span class="h3">Prolonged or recurrent exercise</span><span class="headingEndMark"> — </span>Patients who exercise for more than three hours or more than once a day represent a challenge in that use of a SABA multiple times a day is likely to lead to tachyphylaxis. One might imagine that an inhaled LABA might be useful in this situation. However, in concert with current guidelines, we do not recommend regular use of LABAs (ie, once or twice daily) as monotherapy for EIB, because of concerns about a loss of bronchoprotective effect over time [<a href="#rid30">30,79,80</a>]. Thus, for patients who would require regular, daily dosing of a SABA or LABA to control EIB, we suggest concomitant use of inhaled glucocorticoid or a leukotriene receptor antagonist (LTRA; <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>). (See  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Tolerance'</a>.)</p><p>LTRAs must be taken at least two hours prior to exercise to have a maximal protective effect, but the effect lasts 12 (<a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>) to 24 (<a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>) hours [<a href="#rid30">30</a>]. While not effective in all patients, LTRAs appear superior to LABAs when treating asthmatics with EIB. In one multicenter trial, asthmatics with EIB were randomly assigned to either montelukast or <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> for eight weeks [<a href="#rid81">81</a>]. Therapy was protective within three days for both groups; however, tolerance to salmeterol developed, and by eight weeks, the bronchoprotective effect of montelukast was significantly better  (<a class="graphic graphic_figure graphicRef69196" href="/z/d/graphic/69196.html" rel="external">figure 3</a>).</p><p>As mentioned above, children with EIB can pose a therapeutic challenge, because they tend to exercise intermittently throughout the day and often neglect to premedicate with an inhaled SABA. LTRAs are an effective option in this setting. In a randomized trial of EIB in children, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> and montelukast with <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> were superior to budesonide and budesonide with <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> [<a href="#rid82">82</a>].</p><p>Improving asthma control to the point that specific pretreatment is not necessary before exercise is an additional strategy. This goal can often be accomplished with use of inhaled glucocorticoids according to current guidelines [<a href="#rid30">30,66</a>]. (See <a class="local">'Persistent EIB symptoms despite premedication'</a> below and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p class="headingAnchor" id="H1578939735"><span class="h3">Persistent EIB symptoms despite premedication</span><span class="headingEndMark"> — </span>When EIB is refractory to premedication with a SABA, poor asthma control is often the cause. The most effective method of achieving asthma control involves appropriate step-up therapies including the use of inhaled glucocorticoids  (<a class="graphic graphic_table graphicRef58247 graphicRef71181 graphicRef80908" href="/z/d/graphic/58247.html" rel="external">table 4A-C</a>). Other agents frequently involved in asthma control of these patients include inhaled glucocorticoid-LABA combination therapies, or leukotriene receptor antagonists (LTRA). (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management", section on 'Initiating pharmacologic treatment'</a> and  <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">"Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"</a>.)</p><p>Although inhaled glucocorticoids do not have an immediate protective effect on EIB, they do improve airway hyperresponsiveness and, over weeks to months, decrease the magnitude of bronchoconstriction that occurs with a given workload [<a href="#rid82">82-85</a>]. Some studies have noted that inhaled glucocorticoids do not decrease EIB in a dose-related manner [<a href="#rid59">59,60</a>]. In contrast, a decrease in <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> sensitivity (as determined by methacholine challenge) is generally well-correlated with the inhaled glucocorticoid dose. These findings suggest both a mechanism for EIB distinct from methacholine, and considerable variability in response to inhaled glucocorticoid therapy. This variability is partially explained by a greater magnitude of benefit from inhaled glucocorticoids in patients with higher sputum eosinophilia [<a href="#rid9">9</a>].</p><p>Inhaled glucocorticoids do not require a therapeutic use exception (TUE) from the World Anti-Doping Agency [<a href="#rid86">86</a>], although oral and intravenous glucocorticoids do require a TUE. (See <a class="local">'World Anti-Doping Agency'</a> below.)</p><p class="headingAnchor" id="H1578939761"><span class="h3">Refractory EIB due to extreme conditions</span><span class="headingEndMark"> — </span>Data are limited in terms of strategies to prevent EIB in high performance athletes and patients exercising in extreme conditions (eg, very cold, dry air). Therapies that may be useful when added to pretreatment with a SABA include regular use of an LTRA (eg, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>) or pretreatment with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> [<a href="#rid87">87</a>]. Nonpharmacologic measures may also be helpful. (See  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma", section on 'Clinical use of leukotriene-modifying drugs in asthma'</a> and <a class="local">'Nonpharmacologic measures to reduce EIB'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukotriene receptor antagonists</strong> – LTRAs, when added to pretreatment with a SABA may provide better protection in extreme conditions than either agent alone, based on clinical experience [<a href="#rid88">88</a>], although the response is variable [<a href="#rid87">87,89</a>]. LTRAs do not require a TUE from the World Anti-Doping Agency (WADA). (See <a class="local">'World Anti-Doping Agency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> – Among elite cross-country skiers, inhaled ipratropium was associated with greater improvement in FEV<sub>1</sub> than inhaled <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (salbutamol) [<a href="#rid90">90</a>]. In addition, the improvement in FEV<sub>1</sub> correlated with greater airways hyperresponsiveness to <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> challenge. Whether this response to ipratropium translates into better protection against EIB during high intensity cold air exercise has not been determined.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Dietary modification</span><span class="headingEndMark"> — </span>Data are inconclusive about whether dietary interventions are useful in the management of EIB. Diets rich in anti-inflammatory omega-3 fatty acids have not been conclusively demonstrated to be helpful in the general population of patients with asthma [<a href="#rid91">91</a>]. Despite early data suggesting benefit of increased dietary omega-3 fatty acids in EIB, subsequent data do not support a benefit [<a href="#rid30">30,92,93</a>]. In a randomized trial of 23 patients treated for three weeks with either fish oil supplements (containing omega-3 fatty acids) or placebo, the group on fish oil was not different from control in sputum eosinophils, FEV<sub>1</sub> percent predicted, symptom score, or response to <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> challenge (a surrogate for EIB) [<a href="#rid93">93</a>].</p><p>Systematic reviews have reached different opinions about the effect of <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a> in reducing EIB possibly due to the small number of subjects and differing choices of outcome measurements [<a href="#rid94">94,95</a>]. Overall, the data appear inconclusive. Lycopene supplements have not been shown to reduce EIB [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Other types of asthma therapy are <strong>not</strong> very effective in protecting against EIB. As an example, oral beta-2 agonists and methylxanthines are marginally effective or ineffective in almost all patients [<a href="#rid96">96,97</a>].</p><p>Oral antihistamines appear to provide modest protection against EIB in patients with inhalant allergies, but not in nonatopic patients [<a href="#rid30">30</a>].</p><p>Several other drugs have been tested as possible prophylactic agents against EIB. Inhaled medications, such as <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> [<a href="#rid98">98</a>], prostaglandin E2 [<a href="#rid99">99</a>], <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid100">100</a>], and heparin [<a href="#rid101">101</a>], may protect against EIB. However, long-term clinical use of these compounds has not been directly compared with the prophylactic use of inhaled beta-2 agonists. For this reason, their role in clinical practice is unclear.</p><p class="headingAnchor" id="H1578940505"><span class="h1">WORLD ANTI-DOPING AGENCY</span><span class="headingEndMark"> — </span>The World Anti-Doping Agency (WADA), which governs medication use by athletes in international competition, has published guidelines for the diagnosis and management of asthma in athletes [<a href="#rid102">102</a>] and a list of medications that require a Therapeutic Use Exemption (TUE) [<a href="#rid86">86</a>].</p><p>The WADA lists beta-agonists on its prohibited medication list due to concerns about performance enhancement [<a href="#rid53">53,86</a>]. However, inhaled <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (salbutamol), maximum dose 1600 mcg/24 hours and 800 mcg/12 hours, inhaled <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, maximum delivered dose 54 mcg/24 hours, and inhaled <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>, maximum dose 200 mcg/24 hours, are acceptable and do not need a Therapeutic Use Exception [<a href="#rid86">86</a>]. Nebulized beta-agonists may reach levels above those permitted. Urinary levels of albuterol over 1000 ng/mL or formoterol over 40 ng/mL are considered to be in excess of therapeutic use to prevent EIB.</p><p>In terms of potential effects on performance, a study of 16 athletes found that high-dose salbutamol (<a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) 1600 mcg/day for six weeks did not increase strength, power, or endurance relative to placebo [<a href="#rid103">103</a>].</p><p>Inhaled glucocorticoids are permitted by the WADA and do not need a Therapeutic Use Exception [<a href="#rid86">86</a>]. Systemic glucocorticoids are prohibited in competition, and a Therapeutic Use Exception may need to be filed for use outside of competition [<a href="#rid86">86,104</a>]. Leukotriene receptor antagonists (<a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>) and <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> are permitted agents.</p><p class="headingAnchor" id="H612788166"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122209.html" rel="external">"Society guideline links: Exercise-induced bronchoconstriction"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/112887.html" rel="external">"Patient education: Exercise-induced asthma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/376.html" rel="external">"Patient education: Exercise-induced asthma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Exercise-induced bronchoconstriction (EIB) refers to the episodic bronchoconstriction that follows exercise in many asthmatic patients. The term EIB reflects the view that exercise is a trigger of bronchoconstriction in patients with underlying asthma. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance measures</strong> – Improving a patient's cardiovascular fitness reduces the minute ventilation required for a given level of exercise, thereby decreasing the stimulus for bronchoconstriction. Avoiding exercise in cold, dry air can also reduce the stimulus for exercise-induced bronchoconstriction. (See <a class="local">'Nonpharmacologic measures to reduce EIB'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic therapy</strong> – Therapy for EIB varies somewhat with the clinical setting  (<a class="graphic graphic_table graphicRef105874" href="/z/d/graphic/105874.html" rel="external">table 1</a>). All patients with EIB should have access to a short-acting beta-agonist (SABA) available when exercising for relief of asthma symptoms. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pre-exercise treatments for EIB</strong> – For patients who have otherwise well-controlled asthma, but who frequently have asthma symptoms with exercise, we recommend prophylactic use of a SABA (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> 90 mcg/inhalation, 2 inhalations) <strong>or</strong> combination inhaled glucocorticoid and <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> (eg, <a class="drug drug_general" data-topicid="8524" href="/z/d/drug information/8524.html" rel="external">budesonide-formoterol</a> 160 mcg/4.5 mcg, 1 inhalation), approximately 5 to 20 minutes prior to exercise rather than observation alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Pre-exercise treatments for EIB'</a> above.)</p><p></p><p class="bulletIndent2">Alternatives for prophylaxis in patients who prefer not to use or cannot tolerate a SABA include leukotriene receptor antagonists (LTRA) or inhaled <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>. However, neither of these alternatives reverse bronchoconstriction as rapidly as a SABA or <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, so the patient will still need to keep a SABA- or formoterol-containing inhaler on hand for break-through symptoms. (See <a class="local">'Approach in patients with intolerance of short-acting beta-agonists'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prolonged or recurrent exercise</strong> – For patients who require daily therapy for EIB due to prolonged or recurrent exercise, we suggest regular use of an LTRA or an inhaled glucocorticoid in addition to a short-acting beta-agonist, rather than regular daily use of a beta-agonist alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The use of an LTRA may be particularly attractive in children, in whom exercise may be unpredictable or repeated throughout the day, and who may not use their inhalers as directed. (See <a class="local">'Prolonged or recurrent exercise'</a> above and <a class="local">'Pre-exercise treatments for EIB'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent EIB symptoms despite pretreatment</strong> – Most patients with persistent EIB symptoms despite use of exercise pretreatment therapies have undiagnosed poorly controlled asthma. For these patients, asthma control should be prioritized with step-up therapy including an inhaled glucocorticoid, inhaled glucocorticoid-LABA combination, or LTRA. (See <a class="local">'Persistent EIB symptoms despite premedication'</a> above and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ineffective treatments</strong> – Antihistamines, <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> and oral beta agonists are minimally effective or ineffective for EIB. (See <a class="local">'Other therapies'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Storms WW. Asthma associated with exercise. Immunol Allergy Clin North Am 2005; 25:31.</a></li><li><a class="nounderline abstract_t">Lucas SR, Platts-Mills TA. Physical activity and exercise in asthma: relevance to etiology and treatment. J Allergy Clin Immunol 2005; 115:928.</a></li><li><a class="nounderline abstract_t">Sonna LA, Angel KC, Sharp MA, et al. The prevalence of exercise-induced bronchospasm among US Army recruits and its effects on physical performance. Chest 2001; 119:1676.</a></li><li><a class="nounderline abstract_t">Ng'ang'a LW, Odhiambo JA, Mungai MW, et al. Prevalence of exercise induced bronchospasm in Kenyan school children: an urban-rural comparison. Thorax 1998; 53:919.</a></li><li><a class="nounderline abstract_t">Kukafka DS, Lang DM, Porter S, et al. Exercise-induced bronchospasm in high school athletes via a free running test: incidence and epidemiology. Chest 1998; 114:1613.</a></li><li><a class="nounderline abstract_t">Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. J Allergy Clin Immunol 2016; 138:1292.</a></li><li><a class="nounderline abstract_t">Weiler JM, Bonini S, Coifman R, et al. American Academy of Allergy, Asthma &amp; Immunology Work Group report: exercise-induced asthma. J Allergy Clin Immunol 2007; 119:1349.</a></li><li><a class="nounderline abstract_t">Anderton RC, Cuff MT, Frith PA, et al. Bronchial responsiveness to inhaled histamine and exercise. J Allergy Clin Immunol 1979; 63:315.</a></li><li><a class="nounderline abstract_t">Duong M, Subbarao P, Adelroth E, et al. Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma. Chest 2008; 133:404.</a></li><li><a class="nounderline abstract_t">Mountjoy M, Fitch K, Boulet LP, et al. Prevalence and characteristics of asthma in the aquatic disciplines. J Allergy Clin Immunol 2015; 136:588.</a></li><li><a class="nounderline abstract_t">Bonini M, Gramiccioni C, Fioretti D, et al. Asthma, allergy and the Olympics: a 12-year survey in elite athletes. Curr Opin Allergy Clin Immunol 2015; 15:184.</a></li><li><a class="nounderline abstract_t">Teixeira RN, Teixeira LR, Costa LA, et al. Exercise-induced bronchoconstriction in elite long-distance runners in Brazil. J Bras Pneumol 2012; 38:292.</a></li><li><a class="nounderline abstract_t">Bougault V, Turmel J, Boulet LP. Bronchial challenges and respiratory symptoms in elite swimmers and winter sport athletes: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138:31S.</a></li><li><a class="nounderline abstract_t">McFadden ER Jr, Ingram RH Jr. Exercise-induced asthma: Observations on the initiating stimulus. N Engl J Med 1979; 301:763.</a></li><li><a class="nounderline abstract_t">Anderson SD, Schoeffel RE, Black JL, Daviskas E. Airway cooling as the stimulus to exercise-induced asthma--a re-evaluation. Eur J Respir Dis 1985; 67:20.</a></li><li><a class="nounderline abstract_t">Deal EC Jr, McFadden ER Jr, Ingram RH Jr, et al. Role of respiratory heat exchange in production of exercise-induced asthma. J Appl Physiol Respir Environ Exerc Physiol 1979; 46:467.</a></li><li><a class="nounderline abstract_t">Kallings LV, Emtner M, Bäcklund L. Exercise-induced bronchoconstriction in adults with asthma--comparison between running and cycling and between cycling at different air conditions. Ups J Med Sci 1999; 104:191.</a></li><li><a class="nounderline abstract_t">Freed AN, Davis MS. Hyperventilation with dry air increases airway surface fluid osmolality in canine peripheral airways. Am J Respir Crit Care Med 1999; 159:1101.</a></li><li><a class="nounderline abstract_t">Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52:1030.</a></li><li><a class="nounderline abstract_t">Hartley JP, Nogrady SG. Effect of an inhaled antihistamine on exercise-induced asthma. Thorax 1980; 35:675.</a></li><li><a class="nounderline abstract_t">Hashimoto S, Gon Y, Matsumoto K, et al. Inhalant corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells. Am J Respir Crit Care Med 2000; 162:1075.</a></li><li><a class="nounderline abstract_t">Hallstrand TS, Ault KA, Bates PW, et al. Peripheral blood manifestations of T(H)2 lymphocyte activation in stable atopic asthma and during exercise-induced bronchospasm. Ann Allergy Asthma Immunol 1998; 80:424.</a></li><li><a class="nounderline abstract_t">Kivity S, Argaman A, Onn A, et al. Eosinophil influx into the airways in patients with exercise-induced asthma. Respir Med 2000; 94:1200.</a></li><li><a class="nounderline abstract_t">Yoshikawa T, Shoji S, Fujii T, et al. Severity of exercise-induced bronchoconstriction is related to airway eosinophilic inflammation in patients with asthma. Eur Respir J 1998; 12:879.</a></li><li><a class="nounderline abstract_t">Gauvreau GM, Ronnen GM, Watson RM, O'Byrne PM. Exercise-induced bronchoconstriction does not cause eosinophilic airway inflammation or airway hyperresponsiveness in subjects with asthma. Am J Respir Crit Care Med 2000; 162:1302.</a></li><li><a class="nounderline abstract_t">De Gouw HW, Marshall-Partridge SJ, Van Der Veen H, et al. Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects. J Appl Physiol (1985) 2001; 90:586.</a></li><li><a class="nounderline abstract_t">Scollo M, Zanconato S, Ongaro R, et al. Exhaled nitric oxide and exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 2000; 161:1047.</a></li><li><a class="nounderline abstract_t">Shin HW, Schwindt CD, Aledia AS, et al. Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry. Am J Physiol Regul Integr Comp Physiol 2006; 291:R1741.</a></li><li><a class="nounderline abstract_t">Inman MD, Watson RM, Killian KJ, O'Byrne PM. Methacholine airway responsiveness decreases during exercise in asthmatic subjects. Am Rev Respir Dis 1990; 141:1414.</a></li><li><a class="nounderline abstract_t">Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013; 187:1016.</a></li><li><a class="nounderline abstract_t">Edmunds AT, Tooley M, Godfrey S. The refractory period after exercise-induced asthma: its duration and relation to the severity of exercise. Am Rev Respir Dis 1978; 117:247.</a></li><li><a class="nounderline abstract_t">Manning PJ, Watson RM, O'Byrne PM. Exercise-induced refractoriness in asthmatic subjects involves leukotriene and prostaglandin interdependent mechanisms. Am Rev Respir Dis 1993; 148:950.</a></li><li><a class="nounderline abstract_t">Iikura Y, Inui H, Nagakura T, Lee TH. Factors predisposing to exercise-induced late asthmatic responses. J Allergy Clin Immunol 1985; 75:285.</a></li><li><a class="nounderline abstract_t">Rubinstein I, Levison H, Slutsky AS, et al. Immediate and delayed bronchoconstriction after exercise in patients with asthma. N Engl J Med 1987; 317:482.</a></li><li><a class="nounderline abstract_t">Chhabra SK, Ojha UC. Late asthmatic response in exercise-induced asthma. Ann Allergy Asthma Immunol 1998; 80:323.</a></li><li><a class="nounderline abstract_t">Koh YY, Jeong JH, Jin SM, et al. The occurrence of late asthmatic response to exercise after allergen challenge. Ann Allergy Asthma Immunol 1998; 81:366.</a></li><li><a class="nounderline abstract_t">Tateishi K, Motojima S, Kushima A, et al. Comparison between allergen-induced and exercise-induced asthma with respect to the late asthmatic response, airway responsiveness, and Creola bodies in sputum. Ann Allergy Asthma Immunol 1996; 77:229.</a></li><li><a class="nounderline abstract_t">Helenius IJ, Tikkanen HO, Haahtela T. Occurrence of exercise induced bronchospasm in elite runners: dependence on atopy and exposure to cold air and pollen. Br J Sports Med 1998; 32:125.</a></li><li><a class="nounderline abstract_t">Karjalainen J, Lindqvist A, Laitinen LA. Seasonal variability of exercise-induced asthma especially outdoors. Effect of birch pollen allergy. Clin Exp Allergy 1989; 19:273.</a></li><li class="breakAll">International Olympic Committee. IOC Consensus Statement on Asthma in Elite Athletes. January 2008. http://www.olympic.org/Documents/Reports/EN/en_report_1301.pdf (Accessed on October 29, 2015).</li><li><a class="nounderline abstract_t">Bonini S, Brusasco V, Carlsen KH, et al. Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. Allergy 2004; 59:33.</a></li><li><a class="nounderline abstract_t">Anderson SD, Fitch K, Perry CP, et al. Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. J Allergy Clin Immunol 2003; 111:45.</a></li><li><a class="nounderline abstract_t">Anderson SD, Sue-Chu M, Perry CP, et al. Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol 2006; 117:767.</a></li><li><a class="nounderline abstract_t">Rundell KW, Anderson SD, Spiering BA, Judelson DA. Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes. Chest 2004; 125:909.</a></li><li><a class="nounderline abstract_t">Brannan JD, Koskela H, Anderson SD, Chew N. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. Am J Respir Crit Care Med 1998; 158:1120.</a></li><li><a class="nounderline abstract_t">Boulet LP, O'Byrne PM. Asthma and exercise-induced bronchoconstriction in athletes. N Engl J Med 2015; 372:641.</a></li><li><a class="nounderline abstract_t">Rundell KW, Slee JB. Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes. J Allergy Clin Immunol 2008; 122:238.</a></li><li><a class="nounderline abstract_t">Reier-Nilsen T, Sewry N, Chenuel B, et al. Diagnostic approach to lower airway dysfunction in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus on 'acute respiratory illness in the athlete'. Br J Sports Med 2023; 57:481.</a></li><li><a class="nounderline abstract_t">Nielsen EW, Hull JH, Backer V. High prevalence of exercise-induced laryngeal obstruction in athletes. Med Sci Sports Exerc 2013; 45:2030.</a></li><li><a class="nounderline abstract_t">Johansson H, Norlander K, Berglund L, et al. Prevalence of exercise-induced bronchoconstriction and exercise-induced laryngeal obstruction in a general adolescent population. Thorax 2015; 70:57.</a></li><li><a class="nounderline abstract_t">Maat RC, Røksund OD, Halvorsen T, et al. Audiovisual assessment of exercise-induced laryngeal obstruction: reliability and validity of observations. Eur Arch Otorhinolaryngol 2009; 266:1929.</a></li><li><a class="nounderline abstract_t">Weinberger M, Abu-Hasan M. Pseudo-asthma: when cough, wheezing, and dyspnea are not asthma. Pediatrics 2007; 120:855.</a></li><li><a class="nounderline abstract_t">Zeiger JS, Weiler JM. Special Considerations and Perspectives for Exercise-Induced Bronchoconstriction (EIB) in Olympic and Other Elite Athletes. J Allergy Clin Immunol Pract 2020; 8:2194.</a></li><li><a class="nounderline abstract_t">Boulding R, Stacey R, Niven R, Fowler SJ. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev 2016; 25:287.</a></li><li><a class="nounderline abstract_t">Denton E, Bondarenko J, O'Hehir RE, Hew M. Breathing pattern disorder in difficult asthma: Characteristics and improvement in asthma control and quality of life after breathing re-training. Allergy 2019; 74:201.</a></li><li><a class="nounderline abstract_t">van Dixhoorn J, Folgering H. The Nijmegen Questionnaire and dysfunctional breathing. ERJ Open Res 2015; 1.</a></li><li><a class="nounderline abstract_t">Denton E, Bondarenko J, Tay T, et al. Factors Associated with Dysfunctional Breathing in Patients with Difficult to Treat Asthma. J Allergy Clin Immunol Pract 2019; 7:1471.</a></li><li><a class="nounderline abstract_t">Abu-Hasan M, Tannous B, Weinberger M. Exercise-induced dyspnea in children and adolescents: if not asthma then what? Ann Allergy Asthma Immunol 2005; 94:366.</a></li><li><a class="nounderline abstract_t">Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29:415.</a></li><li><a class="nounderline abstract_t">Freezer NJ, Croasdell H, Doull IJ, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Eur Respir J 1995; 8:1488.</a></li><li><a class="nounderline abstract_t">Millqvist E, Bake B, Bengtsson U, Löwhagen O. A breathing filter exchanging heat and moisture prevents asthma induced by cold air. Allergy 1995; 50:225.</a></li><li><a class="nounderline abstract_t">Beuther DA, Martin RJ. Efficacy of a heat exchanger mask in cold exercise-induced asthma. Chest 2006; 129:1188.</a></li><li><a class="nounderline abstract_t">Stickland MK, Rowe BH, Spooner CH, et al. Effect of warm-up exercise on exercise-induced bronchoconstriction. Med Sci Sports Exerc 2012; 44:383.</a></li><li><a class="nounderline abstract_t">Rundell KW, Spiering BA, Judelson DA, Wilson MH. Bronchoconstriction during cross-country skiing: is there really a refractory period? Med Sci Sports Exerc 2003; 35:18.</a></li><li><a class="nounderline abstract_t">Rundell KW, Sue-Chu M. Air quality and exercise-induced bronchoconstriction in elite athletes. Immunol Allergy Clin North Am 2013; 33:409.</a></li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Bonini M, Di Mambro C, Calderon MA, et al. Beta₂-agonists for exercise-induced asthma. Cochrane Database Syst Rev 2013; :CD003564.</a></li><li><a class="nounderline abstract_t">Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014; 69:130.</a></li><li><a class="nounderline abstract_t">Richter K, Janicki S, Jörres RA, Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 2002; 19:865.</a></li><li><a class="nounderline abstract_t">Hancox RJ, Subbarao P, Kamada D, et al. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002; 165:1068.</a></li><li><a class="nounderline abstract_t">Newnham DM, Ingram CG, Earnshaw J, et al. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med 1993; 87:439.</a></li><li><a class="nounderline abstract_t">Vilsvik J, Ankerst J, Palmqvist M, et al. Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis. Respir Med 2001; 95:484.</a></li><li><a class="nounderline abstract_t">Philip G, Villarán C, Pearlman DS, et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44:213.</a></li><li><a class="nounderline abstract_t">Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006; 97:98.</a></li><li><a class="nounderline abstract_t">Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147.</a></li><li><a class="nounderline abstract_t">Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133:424.</a></li><li><a class="nounderline abstract_t">Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, et al. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2002; 32:1360.</a></li><li><a class="nounderline abstract_t">Spooner CH, Spooner GR, Rowe BH. Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2003; :CD002307.</a></li><li><a class="nounderline abstract_t">Dryden DM, Spooner CH, Stickland MK, et al. Exercise-induced bronchoconstriction and asthma. Evid Rep Technol Assess (Full Rep) 2010; :1.</a></li><li><a class="nounderline abstract_t">Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153:65.</a></li><li><a class="nounderline abstract_t">Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000; 132:97.</a></li><li><a class="nounderline abstract_t">Stelmach I, Grzelewski T, Majak P, et al. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008; 121:383.</a></li><li><a class="nounderline abstract_t">Jónasson G, Carlsen KH, Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren. Pediatr Allergy Immunol 2000; 11:120.</a></li><li><a class="nounderline abstract_t">Jónasson G, Carlsen KH, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J 1998; 12:1099.</a></li><li><a class="nounderline abstract_t">Koh MS, Tee A, Lasserson TJ, Irving LB. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database Syst Rev 2007; :CD002739.</a></li><li class="breakAll">World Anti-Doping Agency www.wada-ama.org (Accessed on July 23, 2020).</li><li><a class="nounderline abstract_t">Koya T, Ueno H, Hasegawa T, et al. Management of Exercise-Induced Bronchoconstriction in Athletes. J Allergy Clin Immunol Pract 2020; 8:2183.</a></li><li><a class="nounderline abstract_t">Carlsen KH. Sports in extreme conditions: the impact of exercise in cold temperatures on asthma and bronchial hyper-responsiveness in athletes. Br J Sports Med 2012; 46:796.</a></li><li><a class="nounderline abstract_t">Helenius I, Lumme A, Ounap J, et al. No effect of montelukast on asthma-like symptoms in elite ice hockey players. Allergy 2004; 59:39.</a></li><li><a class="nounderline abstract_t">Stang J, Couto M, Carlsen KH, Stensrud T. Increased bronchial parasympathetic tone in elite cross-country and biathlon skiers: a randomised crossover study. Br J Sports Med 2014.</a></li><li><a class="nounderline abstract_t">Reisman J, Schachter HM, Dales RE, et al. Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review. BMC Complement Altern Med 2006; 6:26.</a></li><li><a class="nounderline abstract_t">Mickleborough TD, Lindley MR, Ionescu AA, Fly AD. Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest 2006; 129:39.</a></li><li><a class="nounderline abstract_t">Brannan JD, Bood J, Alkhabaz A, et al. The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma. Chest 2015; 147:397.</a></li><li><a class="nounderline abstract_t">Hemilä H. The effect of vitamin C on bronchoconstriction and respiratory symptoms caused by exercise: a review and statistical analysis. Allergy Asthma Clin Immunol 2014; 10:58.</a></li><li><a class="nounderline abstract_t">Milan SJ, Hart A, Wilkinson M. Vitamin C for asthma and exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2013; :CD010391.</a></li><li><a class="nounderline abstract_t">Ellis EF. Inhibition of exercise-induced asthma by theophylline. J Allergy Clin Immunol 1984; 73:690.</a></li><li><a class="nounderline abstract_t">Fuglsang G, Hertz B, Holm EB. No protection by oral terbutaline against exercise-induced asthma in children: a dose-response study. Eur Respir J 1993; 6:527.</a></li><li><a class="nounderline abstract_t">Bianco S, Vaghi A, Robuschi M, Pasargiklian M. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 1988; 2:252.</a></li><li><a class="nounderline abstract_t">Melillo E, Woolley KL, Manning PJ, et al. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994; 149:1138.</a></li><li><a class="nounderline abstract_t">Shimizu T, Mochizuki H, Shigeta M, Morikawa A. Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Am J Respir Crit Care Med 1997; 155:170.</a></li><li><a class="nounderline abstract_t">Ahmed T, Gonzalez BJ, Danta I. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med 1999; 160:576.</a></li><li class="breakAll">World Anti-Doping Agency. Therapeutic Use Exemption Physician Guidelines: Asthma. https://www.wada-ama.org/sites/default/files/resources/files/tuec_asthma_version6.1.pdf (Accessed on July 23, 2020).</li><li><a class="nounderline abstract_t">Dickinson J, Molphy J, Chester N, et al. The ergogenic effect of long-term use of high dose salbutamol. Clin J Sport Med 2014; 24:474.</a></li><li><a class="nounderline abstract_t">Fitch K. The World Anti-Doping Code: can you have asthma and still be an elite athlete? Breathe (Sheff) 2016; 12:148.</a></li></ol></div><div id="topicVersionRevision">Topic 533 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579363" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Asthma associated with exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867847" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Physical activity and exercise in asthma: relevance to etiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399690" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The prevalence of exercise-induced bronchospasm among US Army recruits and its effects on physical performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193388" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of exercise induced bronchospasm in Kenyan school children: an urban-rural comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9872197" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Exercise-induced bronchospasm in high school athletes via a free running test: incidence and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27665489" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Exercise-induced bronchoconstriction update-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17433829" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : American Academy of Allergy, Asthma&amp;Immunology Work Group report: exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/429710" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bronchial responsiveness to inhaled histamine and exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071011" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25819982" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence and characteristics of asthma in the aquatic disciplines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961393" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Asthma, allergy and the Olympics: a 12-year survey in elite athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22782598" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Exercise-induced bronchoconstriction in elite long-distance runners in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20363843" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bronchial challenges and respiratory symptoms in elite swimmers and winter sport athletes: Airway hyperresponsiveness in asthma: its measurement and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/39252" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Exercise-induced asthma: Observations on the initiating stimulus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4054253" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Airway cooling as the stimulus to exercise-induced asthma--a re-evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/438014" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of respiratory heat exchange in production of exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680952" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Exercise-induced bronchoconstriction in adults with asthma--comparison between running and cycling and between cycling at different air conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194152" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hyperventilation with dry air increases airway surface fluid osmolality in canine peripheral airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516894" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7003797" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of an inhaled antihistamine on exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10988133" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Inhalant corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609615" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Peripheral blood manifestations of T(H)2 lymphocyte activation in stable atopic asthma and during exercise-induced bronchospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11192956" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Eosinophil influx into the airways in patients with exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817162" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Severity of exercise-induced bronchoconstriction is related to airway eosinophilic inflammation in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11029335" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Exercise-induced bronchoconstriction does not cause eosinophilic airway inflammation or airway hyperresponsiveness in subjects with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160057" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10712361" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Exhaled nitric oxide and exercise-induced bronchoconstriction in asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840654" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2190506" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Methacholine airway responsiveness decreases during exercise in asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23634861" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/637407" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The refractory period after exercise-induced asthma: its duration and relation to the severity of exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214949" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Exercise-induced refractoriness in asthmatic subjects involves leukotriene and prostaglandin interdependent mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3968338" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Factors predisposing to exercise-induced late asthmatic responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3614292" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immediate and delayed bronchoconstriction after exercise in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9564982" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Late asthmatic response in exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9809502" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The occurrence of late asthmatic response to exercise after allergen challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8814050" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison between allergen-induced and exercise-induced asthma with respect to the late asthmatic response, airway responsiveness, and Creola bodies in sputum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631218" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Occurrence of exercise induced bronchospasm in elite runners: dependence on atopy and exposure to cold air and pollen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2736428" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Seasonal variability of exercise-induced asthma especially outdoors. Effect of birch pollen allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2736428" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Seasonal variability of exercise-induced asthma especially outdoors. Effect of birch pollen allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14674930" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12532095" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630932" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006949" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9769270" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671256" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Asthma and exercise-induced bronchoconstriction in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678339" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36717213" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnostic approach to lower airway dysfunction in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus on 'acute respiratory illness in the athlete'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23657163" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : High prevalence of exercise-induced laryngeal obstruction in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25380758" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence of exercise-induced bronchoconstriction and exercise-induced laryngeal obstruction in a general adolescent population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19585139" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Audiovisual assessment of exercise-induced laryngeal obstruction: reliability and validity of observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908773" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pseudo-asthma: when cough, wheezing, and dyspnea are not asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32006727" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Special Considerations and Perspectives for Exercise-Induced Bronchoconstriction (EIB) in Olympic and Other Elite Athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27581828" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dysfunctional breathing: a review of the literature and proposal for classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30243028" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Breathing pattern disorder in difficult asthma: Characteristics and improvement in asthma control and quality of life after breathing re-training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27730128" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The Nijmegen Questionnaire and dysfunctional breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30529061" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Factors Associated with Dysfunctional Breathing in Patients with Difficult to Treat Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801248" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Exercise-induced dyspnea in children and adolescents: if not asthma then what?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821721" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8575573" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7677239" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A breathing filter exchanging heat and moisture prevents asthma induced by cold air.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685008" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Efficacy of a heat exchanger mask in cold exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21811185" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of warm-up exercise on exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12544630" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bronchoconstriction during cross-country skiing: is there really a refractory period?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23830133" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Air quality and exercise-induced bronchoconstriction in elite athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23830133" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Air quality and exercise-induced bronchoconstriction in elite athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24089311" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Beta₂-agonists for exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092567" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12030726" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956046" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Beta2-agonist tolerance and exercise-induced bronchospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105520" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11421506" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17454341" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16892789" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9664090" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738728" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220476" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583951" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20726625" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Exercise-induced bronchoconstriction and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542164" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The effect of regular inhaled albuterol on exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10644288" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980416" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893016" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9864004" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636704" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636704" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32620432" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Management of Exercise-Induced Bronchoconstriction in Athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22906782" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sports in extreme conditions: the impact of exercise in cold temperatures on asthma and bronchial hyper-responsiveness in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14674932" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : No effect of montelukast on asthma-like symptoms in elite ice hockey players.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416197" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Increased bronchial parasympathetic tone in elite cross-country and biathlon skiers: a randomised crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16854238" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16424411" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25321659" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25788952" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The effect of vitamin C on bronchoconstriction and respiratory symptoms caused by exercise: a review and statistical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24154977" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Vitamin C for asthma and exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6715732" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Inhibition of exercise-induced asthma by theophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491302" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : No protection by oral terbutaline against exercise-induced asthma in children: a dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899239" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prevention of exercise-induced bronchoconstriction by inhaled frusemide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8173753" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9001307" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430731" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430731" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24451697" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The ergogenic effect of long-term use of high dose salbutamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27408633" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The World Anti-Doping Code: can you have asthma and still be an elite athlete?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
